{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:28:56Z","timestamp":1779888536933,"version":"3.53.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.radonc.2023.109677","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T06:40:50Z","timestamp":1681972850000},"page":"109677","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients"],"prefix":"10.1016","volume":"184","author":[{"given":"Cem","family":"Onal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurcan","family":"Erbay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi","family":"Oymak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan Cem","family":"Guler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109677_b0005","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2023.109677_b0010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0015","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.ijrobp.2004.08.047","article-title":"Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma\u2013long-term results of phase III RTOG 85\u201331","volume":"61","author":"Pilepich","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109677_b0020","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1097\/01.ju.0000157323.55611.23","article-title":"Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer","volume":"173","author":"Vicini","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109677_b0025","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0022-5347(05)64559-4","article-title":"Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer","volume":"168","author":"Kwak","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109677_b0030","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1162\/153535002321093945","article-title":"Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy","volume":"1","author":"Chenevert","year":"2002","journal-title":"Mol Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0035","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.radonc.2022.06.011","article-title":"The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy","volume":"173","author":"Onal","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0040","doi-asserted-by":"crossref","DOI":"10.1002\/jmri.28093","article-title":"Repeatability and reproducibility assessment of the apparent diffusion coefficient in the prostate: a trial of the ECOG-ACRIN Research Group (ACRIN 6701)","author":"Boss","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0045","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/jmri.28061","article-title":"Value of T(2) mapping MRI for prostate cancer detection and classification","volume":"56","author":"Klingebiel","year":"2022","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s00330-010-1999-9","article-title":"Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: initial results","volume":"21","author":"Park","year":"2011","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0055","doi-asserted-by":"crossref","first-page":"e0157313","DOI":"10.1371\/journal.pone.0157313","article-title":"Preoperative multiparametric magnetic resonance imaging predicts biochemical recurrence in prostate cancer after radical prostatectomy","volume":"11","author":"Ho","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2023.109677_b0060","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1016\/j.urolonc.2018.07.004","article-title":"Pretreatment multiparametric MRI is independently associated with biochemical outcome in men treated with radiation therapy for prostate cancer","volume":"36","author":"Kauffmann","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0065","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.brachy.2017.07.008","article-title":"Pretreatment 3T multiparametric MRI staging predicts for biochemical failure in high-risk prostate cancer treated with combination high-dose-rate brachytherapy and external beam radiotherapy","volume":"16","author":"Hegde","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.radonc.2023.109677_b0070","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.ijrobp.2011.06.2009","article-title":"Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer","volume":"83","author":"Park","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109677_b0075","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.radonc.2014.07.016","article-title":"Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T","volume":"113","author":"Decker","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5301\/tj.5000415","article-title":"Diffusion-weighted magnetic resonance imaging in patients with prostate cancer treated with radiotherapy","volume":"102","author":"Iannelli","year":"2016","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2023.109677_b0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.diii.2019.06.003","article-title":"Monitoring radiotherapy induced tissue changes in localized prostate cancer by multi-parametric magnetic resonance imaging (MP-MRI)","volume":"100","author":"Wu","year":"2019","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0090","first-page":"5027","article-title":"Diffusion-weighted MRI provides a useful biomarker for evaluation of radiotherapy efficacy in patients with prostate cancer","volume":"37","author":"Wu","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2023.109677_b0095","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0022-5347(01)64230-7","article-title":"Outcome based staging for clinically localized adenocarcinoma of the prostate","volume":"158","author":"D'Amico","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109677_b0100","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109677_b0105","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00066-017-1131-z","article-title":"The impact of androgen deprivation therapy on setup errors during external beam radiation therapy for prostate cancer","volume":"193","author":"Onal","year":"2017","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.radonc.2023.109677_b0110","doi-asserted-by":"crossref","first-page":"20130617","DOI":"10.1259\/bjr.20130617","article-title":"Simultaneous integrated boost to intraprostatic lesions using different energy levels of intensity-modulated radiotherapy and volumetric-arc therapy","volume":"87","author":"Onal","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0115","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S0360-3016(01)02778-X","article-title":"Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era","volume":"52","author":"Kupelian","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109677_b0120","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1470-2045(07)70143-2","article-title":"Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial","volume":"8","author":"Dearnaley","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0125","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.urology.2009.01.043","article-title":"Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon","volume":"74","author":"Caloglu","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2023.109677_b0130","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/cncr.22183","article-title":"Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis","volume":"107","author":"Horwitz","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2023.109677_b0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2018.11.056","article-title":"Time to prostate-specific antigen nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy","volume":"126","author":"Pike","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2023.109677_b0140","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cam4.1443","article-title":"Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer","volume":"7","author":"Nishimura","year":"2018","journal-title":"Cancer Med"},{"key":"10.1016\/j.radonc.2023.109677_b0145","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.mri.2006.01.001","article-title":"Correlation between metabolite ratios and ADC values of prostate in men with increased PSA level","volume":"24","author":"Kumar","year":"2006","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0150","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/jmri.20477","article-title":"Diffusion-weighted imaging of normal and malignant prostate tissue at 3.0T","volume":"23","author":"Pickles","year":"2006","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0155","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1200\/JCO.2007.11.9610","article-title":"Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology","volume":"25","author":"Hamstra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.mri.2006.09.002","article-title":"Quantitative assessment of intracranial tumor response to dexamethasone using diffusion, perfusion and permeability magnetic resonance imaging","volume":"25","author":"Armitage","year":"2007","journal-title":"Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0165","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1007\/s00330-015-3688-1","article-title":"Prostate Cancer: assessing the effects of androgen-deprivation therapy using quantitative diffusion-weighted and dynamic contrast-enhanced MRI","volume":"25","author":"H\u00f6tker","year":"2015","journal-title":"Eur Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0170","doi-asserted-by":"crossref","first-page":"W645","DOI":"10.2214\/AJR.13.12277","article-title":"Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer","volume":"203","author":"Kim","year":"2014","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.radonc.2023.109677_b0175","doi-asserted-by":"crossref","first-page":"W477","DOI":"10.2214\/AJR.09.3557","article-title":"Assessment of response to radiotherapy for prostate cancer: value of diffusion-weighted MRI at 3 T","volume":"194","author":"Song","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.radonc.2023.109677_b0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","article-title":"Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning","volume":"53","author":"Cellini","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109677_b0185","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2002.01.086","article-title":"Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases","volume":"20","author":"Coen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2023.109677_b0190","first-page":"4467","article-title":"Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy","volume":"32","author":"Iraha","year":"2012","journal-title":"Anticancer Res"},{"key":"10.1016\/j.radonc.2023.109677_b0195","doi-asserted-by":"crossref","first-page":"20140359","DOI":"10.1259\/bjr.20140359","article-title":"Diffusion-weighted MRI in early assessment of tumour response to radiotherapy in high-risk prostate cancer","volume":"87","author":"Liu","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0200","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/jmri.22395","article-title":"Diffusion-weighted imaging of the abdomen at 3.0 Tesla: image quality and apparent diffusion coefficient reproducibility compared with 1.5 Tesla","volume":"33","author":"Rosenkrantz","year":"2011","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.radonc.2023.109677_b0205","first-page":"13","article-title":"Prospective image quality and lesion assessment in the setting of MR-guided radiation therapy of prostate cancer on an MR-Linac at 1.5 T: a comparison to a standard 3 T MRI","author":"Almansour","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109677_b0210","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.crad.2008.02.001","article-title":"Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer","volume":"63","author":"deSouza","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1259\/bjr\/14556365","article-title":"Diffusion-weighted magnetic resonance imaging for monitoring prostate cancer progression in patients managed by active surveillance","volume":"84","author":"Morgan","year":"2011","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2023.109677_b0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2214\/AJR.17.18495","article-title":"Apparent diffusion coefficient values of prostate cancer: comparison of 2D and 3D ROIs","volume":"210","author":"Tamada","year":"2018","journal-title":"AJR Am J Roentgenol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002153?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814023002153?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:25:29Z","timestamp":1759123529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814023002153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":44,"alternative-id":["S0167814023002153"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109677","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of the apparent diffusion coefficient for the early prediction of the treatment response after definitive radiotherapy in prostate cancer patients","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109677","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109677"}}